AJOVista LLC Buys Shares of 178 Humana Inc. (NYSE:HUM)

AJOVista LLC bought a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, Holdings Channel.com reports. The fund bought 178 shares of the insurance provider’s stock, valued at approximately $81,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Morgan Stanley grew its holdings in Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock worth $992,938,000 after purchasing an additional 119,760 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Humana by 35.9% during the third quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after buying an additional 402,559 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock worth $645,850,000 after acquiring an additional 64,245 shares during the last quarter. Invesco Ltd. boosted its stake in Humana by 1.4% during the 3rd quarter. Invesco Ltd. now owns 965,488 shares of the insurance provider’s stock valued at $469,729,000 after purchasing an additional 13,670 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Humana by 39.3% during the 3rd quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock worth $331,743,000 after purchasing an additional 192,546 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of Humana stock traded down $0.44 on Friday, hitting $320.54. 1,802,675 shares of the company traded hands, compared to its average volume of 1,607,966. Humana Inc. has a 12-month low of $298.61 and a 12-month high of $541.21. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm’s 50-day simple moving average is $324.12 and its 200 day simple moving average is $388.34. The company has a market cap of $38.63 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.86 and a beta of 0.49.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same quarter in the prior year, the company earned $9.38 EPS. The firm’s revenue was up 10.7% on a year-over-year basis. Analysts expect that Humana Inc. will post 16.18 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.10%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Barclays cut their target price on Humana from $356.00 to $310.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 2nd. Oppenheimer decreased their target price on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. TheStreet lowered shares of Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Truist Financial reiterated a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Finally, Wells Fargo & Company decreased their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Eleven analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Humana currently has a consensus rating of “Hold” and a consensus price target of $424.50.

Insider Transactions at Humana

In other news, Director Jorge S. Mesquita purchased 545 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was acquired at an average price of $367.09 per share, with a total value of $200,064.05. Following the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.32% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.